Justine Sicari
Critical Care Medicine · Pittsburgh, PANPI 1396387114
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,304 of the $5,576 with a category attached, or 77.2%. 13 manufacturers reported payments, led by GSK at 41.9% of the total. 2025 is the largest year on record at $2,499, more than ten times the $234 reported in 2021.
Across 90 payments — averaging $61.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Pulmonx Corporation$599
- Boehringer Ingelheim$429
- Verona Pharma, Inc.$172
- Amgen$141
- plus $314 from 7 others
What the payments were for
- Consulting fees$1,05019%
- Travel & lodging$1202%
- Food & beverage$4,30477%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $2,339 |
| AstraZeneca | 40 | $1,583 |
| Pulmonx Corporation | 5 | $599 |
| Boehringer Ingelheim | 5 | $429 |
| Verona Pharma, Inc. | 2 | $172 |
| Amgen | 2 | $141 |
| Sanofi | 1 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Electromed, Inc. | 2 | $37 |
| Viatris Specialty LLC | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$1,466
- ZEPHYR ENDOBRONCHIAL VALVE$454
- CHARTIS CATHETER$304
- ZEPHYR DELIVERY CATHETER$304
- PULMONX CHARTIS TABLET CONSOLE$304
- TEZSPIRE$234
- AREXVY$229
- OFEV$220
- BREZTRI$116
- IMFINZI$114
- DUPIXENT$111
- Ohtuvayre$103
- FASENRA$103
How this compares
$5,576 in reported general payments places this provider in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 597 | $446,352 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $71,306 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 114 | $61,190 |
| Breo ElliptaFluticasone/Vilanterol | 116 | $47,184 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 510 | $14,373 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,523 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $13,147 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,673 |
| Spiriva HandihalerTiotropium Bromide | 17 | $9,463 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $8,441 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $7,235 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,413 |
| Roflumilast | 72 | $5,851 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $5,720 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,339 | $560,406844 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,583 | $87,392157 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $429 | $26,67155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Pittsburgh
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Kees PoldermanPittsburgh$85K
- Michael RisbanoPittsburgh$34K
- Raghavan MuruganPittsburgh$33K
- Eric BihlerPittsburgh$22K
- Tiffany DumontPittsburgh$21K
- Amy SchmetzerPittsburgh$13K
- Stephanie BaltajiPittsburgh$10K
- Billie BarkerPittsburgh$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.